Media coverage about VIVUS (NASDAQ:VVUS) has trended somewhat positive recently, Accern reports. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. VIVUS earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.26126761029 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media stories that may have effected Accern’s scoring:
VIVUS (NASDAQ:VVUS) opened at $0.41 on Tuesday. The company has a debt-to-equity ratio of 643.86, a current ratio of 7.47 and a quick ratio of 7.09. The stock has a market capitalization of $43.06, a price-to-earnings ratio of 1.23 and a beta of 0.69. VIVUS has a 12 month low of $0.40 and a 12 month high of $1.38.
VIVUS (NASDAQ:VVUS) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.07. The company had revenue of $15.19 million during the quarter, compared to the consensus estimate of $16.00 million. VIVUS had a return on equity of 344.23% and a net margin of 26.71%. The firm’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.09) EPS. equities research analysts expect that VIVUS will post -0.32 earnings per share for the current fiscal year.
VVUS has been the topic of a number of research reports. ValuEngine lowered VIVUS from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Zacks Investment Research lowered VIVUS from a “buy” rating to a “hold” rating in a research report on Saturday, January 6th.
TRADEMARK VIOLATION WARNING: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/06/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-vivus-vvus-stock-price.html.
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.